Evidence map›Paper›PMID 39871454›Full record

ArticleCell transplantation

Trans-Vessel Wall Cell Transplantation, Engraftment, and Tumor Access in the VX2 Rabbit Model.

Victoria Lövljung, Mathias Waldén, Mikael Sandell, Peter Damberg, Staffan Holmin, Fabian Arnberg Sandor

Abstract read
In one paragraph

Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Victoria LövljungDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.ORCID 0009-0007-4038-7587
Mathias WaldénDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.ORCID 0009-0004-1770-1441
Mikael SandellDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Peter DambergKarolinska Experimental Research and Imaging Centre, Karolinska University Hospital, Stockholm, Sweden.
Staffan HolminDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Fabian Arnberg SandorDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The trans-vessel wall device (TW-device) is a new endovascular tool for precise and safe delivery of various payloads (cells, viral, modified RNA, chemotherapy, growth factors) in oncology and regenerative medicine. The twofold aim of this study was to assess cell engraftment and tumor growth using the TW-device for endovascular transplantation and to evaluate its ability to directly access solid tumors. We used the VX2 model in the rabbit kidney to compare percutaneously implanted fresh VX2 cells with TW-device injections of cryopreserved VX2 cells. We demonstrated the feasibility of endovascular transplantation (

Indexed as

Cell TransplantationAnimalsCell Line, TumorDisease Models, AnimalHumansRabbitscancercell transplantationendovascular cell transplantationendovascular interventionlarge animal tumor modeltrans-vessel wall devicetumor accessVX 2

Identifiers

PMID39871454
PMCPMC11773539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.